These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22110220)

  • 1. ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report.
    Yarom N; Stewart D; Avruch L; Malik R; Wells J; Jonker DJ
    Anticancer Res; 2011 Nov; 31(11):3921-5. PubMed ID: 22110220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
    Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
    Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
    J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary management of adrenocortical carcinoma.
    Zini L; Porpiglia F; Fassnacht M
    Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adrenocortical carcinoma and its treatment].
    Tupikowski W; Bednarek-Tupikowska G; Florczak A
    Postepy Hig Med Dosw (Online); 2004 Feb; 58():27-36. PubMed ID: 15069374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report.
    Beom SH; Lee KW; Yang Y; Choi Y; Song KH; Kim YJ; Kim JH; Bang SM; Chung JH; Lee JS
    Jpn J Clin Oncol; 2011 Nov; 41(11):1287-91. PubMed ID: 21980052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
    Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
    Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry.
    Michalkiewicz E; Sandrini R; Figueiredo B; Miranda EC; Caran E; Oliveira-Filho AG; Marques R; Pianovski MA; Lacerda L; Cristofani LM; Jenkins J; Rodriguez-Galindo C; Ribeiro RC
    J Clin Oncol; 2004 Mar; 22(5):838-45. PubMed ID: 14990639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic chemotherapy for adrenocortical carcinoma.
    Dogliotti L; Berruti A; Pia A; Paccotti P; Alì A; Angeli A
    Minerva Endocrinol; 1995 Mar; 20(1):105-9. PubMed ID: 7544429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenocortical carcinoma.
    van Ditzhuijsen CI; van de Weijer R; Haak HR
    Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenocortical cancer treatment.
    Patalano A; Brancato V; Mantero F
    Horm Res; 2009 Jan; 71 Suppl 1():99-104. PubMed ID: 19153517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Target Approach to Metastatic Adrenal Cell Carcinoma.
    Wahab NA; Zainudin S; AbAziz A; Mustafa N; Sukor N; Kamaruddin NA
    Arch Iran Med; 2016 Sep; 19(9):671-3. PubMed ID: 27631184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
    Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
    Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up.
    Schwarte S; Brabant EG; Bastian L; Bruns F
    Anticancer Res; 2007; 27(4A):1917-20. PubMed ID: 17649795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of adrenocortical carcinoma.
    Fassnacht M; Allolio B
    Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):273-89. PubMed ID: 19500769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
    Kelland L
    Curr Opin Mol Ther; 2007 Feb; 9(1):86-91. PubMed ID: 17330406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.